The biotech stock's shares surged after Barron's said the market is underestimating potential sales of its Duchenne Muscular ...

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...